Status:

WITHDRAWN

Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

Lead Sponsor:

Ablynx, a Sanofi company

Conditions:

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The primary objective of the study is to evaluate the antiviral effect and safety of inhaled ALX-0171 in adults diagnosed with respiratory syncytial virus (RSV) respiratory tract infection after hemat...

Eligibility Criteria

Inclusion

  • Subject has received an HSCT using any conditioning regimen and for any underlying etiology (i.e., subject has received an autologous or allogeneic HSCT)
  • Subject is clinically diagnosed with RSV infection with new onset or acute worsening
  • Symptoms likely related to RSV infection have appeared within 5 days of screening and their severity requires initial or maintained hospitalization.
  • Documented RSV infection in the upper respiratory tract (URT)
  • Subject has:
  • Diagnosis of RSV lower respiratory tract (LRT) disease or
  • Diagnosis of RSV URT disease with high risk of progression to lower respiratory tract infection (LRTI)
  • Others as defined in the protocol

Exclusion

  • Subject has clinically significant bacteremia or fungemia within 7 days of screening
  • Subject has clinically significant bacterial, fungal or viral pneumonia
  • Subject presents evidence of shock requiring intensive care unit (ICU) monitoring and/or vasopressor treatment
  • Subject requires or is expected to require invasive mechanical ventilation or intensive non-invasive respiratory support. Standard oxygen supplementation up to 6 L/minute is permitted provided it can be interrupted for the duration of study drug administration.
  • Others as defined in the protocol

Key Trial Info

Start Date :

February 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03468829

Start Date

February 1 2019

End Date

May 1 2020

Last Update

March 11 2019

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Investigator site

Darlinghurst, Australia

2

Investigator site

Westmead, Australia

3

Investigator site

Leuven, Belgium

4

Investigator site 1

Valencia, Spain